Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

PHASE3RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

September 30, 2028

Conditions
Ovarian CarcinomaFirst Line ChemotherapyDigestive System Disorders
Interventions
DEVICE

transcutaneous auricular vagus nerve stimulation

"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"

DEVICE

Placebo device

"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"

Trial Locations (4)

Unknown

RECRUITING

Centre François Baclesse, Caen

NOT_YET_RECRUITING

CHU CAEN, Caen

NOT_YET_RECRUITING

Centre Oscar Lambret, Lille

NOT_YET_RECRUITING

Centre Henri Becquerel, Rouen

All Listed Sponsors
lead

Centre Francois Baclesse

OTHER